tradingkey.logo

Amneal Pharmaceuticals Inc

AMRX
12.945USD
+0.075+0.58%
交易中 美东报价延迟15分钟
4.07B总市值
726.43市盈率 TTM

Amneal Pharmaceuticals Inc

12.945
+0.075+0.58%

关于 Amneal Pharmaceuticals Inc 公司

Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.

Amneal Pharmaceuticals Inc简介

公司代码AMRX
公司名称Amneal Pharmaceuticals Inc
上市日期Nov 18, 2009
CEOPatel (Chintu)
员工数量8100
证券类型Ordinary Share
年结日Nov 18
公司地址400 Crossing Boulevard, 3rd Floor
城市BRIDGEWATER
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编08807
电话19089473120
网址https://amneal.com/
公司代码AMRX
上市日期Nov 18, 2009
CEOPatel (Chintu)

Amneal Pharmaceuticals Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Chintu Patel
Mr. Chintu Patel
Co-Chief Executive Officer, Co-Founder, Director
Co-Chief Executive Officer, Co-Founder, Director
25.62M
--
Mr. Gautam Patel
Mr. Gautam Patel
Director
Director
1.61M
-8.60%
Mr. Anastasios G. (Tasos) Konidaris
Mr. Anastasios G. (Tasos) Konidaris
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
621.88K
+32.21%
Mr. Shlomo Yanai
Mr. Shlomo Yanai
Independent Director
Independent Director
285.99K
+16.38%
Ms. Nikita Shah
Ms. Nikita Shah
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
191.40K
--
Ms. Deborah M. (Deb) Autor
Ms. Deborah M. (Deb) Autor
Independent Director
Independent Director
93.66K
+75.39%
Mr. Chirag Patel
Mr. Chirag Patel
President, Co-Chief Executive Officer, Co-Founder, Director
President, Co-Chief Executive Officer, Co-Founder, Director
--
--
Mr. Ted Nark
Mr. Ted Nark
Independent Director
Independent Director
--
--
Mr. Paul M. Meister
Mr. Paul M. Meister
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. John J. Kiely
Mr. John J. Kiely
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Chintu Patel
Mr. Chintu Patel
Co-Chief Executive Officer, Co-Founder, Director
Co-Chief Executive Officer, Co-Founder, Director
25.62M
--
Mr. Gautam Patel
Mr. Gautam Patel
Director
Director
1.61M
-8.60%
Mr. Anastasios G. (Tasos) Konidaris
Mr. Anastasios G. (Tasos) Konidaris
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
621.88K
+32.21%
Mr. Shlomo Yanai
Mr. Shlomo Yanai
Independent Director
Independent Director
285.99K
+16.38%
Ms. Nikita Shah
Ms. Nikita Shah
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
191.40K
--
Ms. Deborah M. (Deb) Autor
Ms. Deborah M. (Deb) Autor
Independent Director
Independent Director
93.66K
+75.39%

收入明细

单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
业务USD
名称
营收
占比
Oral solid
178.26M
24.60%
Distribution
99.66M
13.76%
Central Nervous System
83.42M
11.51%
Other dosage forms
68.19M
9.41%
Auto-injector
66.59M
9.19%
其他
228.38M
31.52%
由于公司未披露,未能获取相关数据
业务
地区
业务USD
名称
营收
占比
Oral solid
178.26M
24.60%
Distribution
99.66M
13.76%
Central Nervous System
83.42M
11.51%
Other dosage forms
68.19M
9.41%
Auto-injector
66.59M
9.19%
其他
228.38M
31.52%

股东统计

更新时间: 11月16日 周日
更新时间: 11月16日 周日
持股股东
股东类型
持股股东
持股股东
占比
Patel (Tushar Bhikhubhai)
15.45%
Patel (Chintu)
8.15%
Patel (Dipan)
7.58%
Patel (Chirag K)
7.04%
Akram (Mahesh)
6.54%
其他
55.24%
持股股东
持股股东
占比
Patel (Tushar Bhikhubhai)
15.45%
Patel (Chintu)
8.15%
Patel (Dipan)
7.58%
Patel (Chirag K)
7.04%
Akram (Mahesh)
6.54%
其他
55.24%
股东类型
持股股东
占比
Individual Investor
46.38%
Investment Advisor
19.36%
Investment Advisor/Hedge Fund
11.79%
Hedge Fund
11.60%
Private Equity
3.92%
Research Firm
1.93%
Pension Fund
0.27%
Bank and Trust
0.19%
Family Office
0.03%
其他
4.54%

机构持股

更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
448
154.72M
55.65%
+68.38K
2025Q3
455
154.66M
56.61%
+8.55M
2025Q2
432
145.89M
53.25%
+6.99M
2025Q1
416
138.78M
50.16%
-18.42M
2024Q4
398
129.01M
49.64%
-14.17M
2024Q3
380
143.02M
47.07%
+6.97M
2024Q2
372
135.82M
34.71%
+37.56M
2024Q1
356
97.40M
32.81%
-3.83M
2023Q4
348
89.35M
29.61%
+7.08M
2023Q3
338
82.03M
56.21%
+4.32M
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Patel (Tushar Bhikhubhai)
48.58M
15.47%
-5.00M
-9.33%
Mar 14, 2025
Patel (Chintu)
25.62M
8.16%
+351.47K
+1.39%
Mar 14, 2025
Patel (Dipan)
23.83M
7.6%
--
--
Mar 14, 2025
Patel (Chirag K)
22.13M
7.05%
--
--
Aug 06, 2025
Akram (Mahesh)
20.56M
6.55%
-6.30M
-23.45%
Mar 31, 2025
The Vanguard Group, Inc.
17.49M
5.57%
+1.78M
+11.34%
Jun 30, 2025
Rubric Capital Management LP
11.71M
3.73%
+974.36K
+9.08%
Jun 30, 2025
TPG Capital, L.P.
12.33M
3.93%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
10.64M
3.39%
-499.58K
-4.49%
Jun 30, 2025
Citadel Advisors LLC
5.62M
1.79%
-1.87M
-24.92%
Jun 30, 2025
查看更多

持股ETF

更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
Invesco Pharmaceuticals ETF
3.08%
State Street SPDR S&P Pharmaceuticals ETF
2.01%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2%
Invesco Dorsey Wright Healthcare Momentum ETF
0.99%
Invesco Dorsey Wright SmallCap Momentum ETF
0.83%
First Trust NASDAQ Pharmaceuticals ETF
0.78%
First Trust Small Cap Growth AlphaDEX Fund
0.72%
iShares U.S. Pharmaceuticals ETF
0.68%
ProShares Ultra Nasdaq Biotechnology
0.48%
WisdomTree US SmallCap Fund
0.36%
查看更多
Invesco Pharmaceuticals ETF
占比3.08%
State Street SPDR S&P Pharmaceuticals ETF
占比2.01%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
占比2%
Invesco Dorsey Wright Healthcare Momentum ETF
占比0.99%
Invesco Dorsey Wright SmallCap Momentum ETF
占比0.83%
First Trust NASDAQ Pharmaceuticals ETF
占比0.78%
First Trust Small Cap Growth AlphaDEX Fund
占比0.72%
iShares U.S. Pharmaceuticals ETF
占比0.68%
ProShares Ultra Nasdaq Biotechnology
占比0.48%
WisdomTree US SmallCap Fund
占比0.36%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据

常见问题

Amneal Pharmaceuticals Inc的前五大股东是谁?

Amneal Pharmaceuticals Inc 的前五大股东如下:
Patel (Tushar Bhikhubhai)持有股份:48.58M,占总股份比例:15.47%。
Patel (Chintu)持有股份:25.62M,占总股份比例:8.16%。
Patel (Dipan)持有股份:23.83M,占总股份比例:7.60%。
Patel (Chirag K)持有股份:22.13M,占总股份比例:7.05%。
Akram (Mahesh)持有股份:20.56M,占总股份比例:6.55%。

Amneal Pharmaceuticals Inc的前三大股东类型是什么?

Amneal Pharmaceuticals Inc 的前三大股东类型分别是:
Patel (Tushar Bhikhubhai)
Patel (Chintu)
Patel (Dipan)

有多少机构持有Amneal Pharmaceuticals Inc(AMRX)的股份?

截至2025Q4,共有448家机构持有Amneal Pharmaceuticals Inc的股份,合计持有的股份价值约为154.72M,占公司总股份的55.65%。与2025Q3相比,机构持股有所增加,增幅为-0.96%。

哪个业务部门对Amneal Pharmaceuticals Inc的收入贡献最大?

在FY2025Q2,Oral solid业务部门对Amneal Pharmaceuticals Inc的收入贡献最大,创收178.26M,占总收入的24.60%。
KeyAI